Blood:赖氨酸乙酰转移酶5(Tip60)参与造血干细胞稳态维持

2020-06-19 QQY MedSci原创

条件性敲除小鼠造血系统中赖氨酸乙酰转移酶5(Tip60)可导致胎鼠和成年鼠的HSC缺失; Tip60通过H2A.Z的乙酰化调节参与维持HSC的关键生物学过程的基因。

造血干细胞(HSC)可以在整个生命周期内补充血液系统。它们的两个定义特性,即自我更新和分化,受到表观遗传机制的严格控制。

通过条件性基因敲除小鼠模型,Numata等人发现,无论是在胎鼠还是成年鼠中,赖氨酸乙酰转移酶5(Kat5,又称Tip60)都对维持HSC稳态至关重要;Tip60是依赖其乙酰化活性发挥作用的。

对小鼠的造血干细胞和祖细胞进行全基因组染色质和转录组谱分析发现,Tip60与c-Myc共定位,敲除Tip60可抑制Myc靶基因的表达;Myc靶基因与HSC稳态维持、细胞周期和DNA修复相关的重要生物过程密切相关。

值得注意的是,乙酰化的H2A.Z(acHA.Z)在Tip60结合的活性染色质上富集,敲除Tip60可诱导acHA.Z/H2A.Z比值大幅度下降。

综上所述,这些研究结果揭示了通过Tip60依赖性H2A.Z乙酰化来激活Myc靶基因的HSC维持的关键表观遗传调控机制(至少是部分机制)。

原始出处:

Akihiko Numata,et al. Lysine acetyltransferase Tip60 is required for hematopoietic stem cell maintenance. Blood. June15,2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=954316, encodeId=aeba9543169b, content=受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/e69ebf6de4ff4c58975eca21defba7f4/998f896c1f9b4f698397a269727651c6.jpg, createdBy=7b2b5391720, createdName=ms5000000426001883, createdTime=Tue Apr 06 21:16:10 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646753, encodeId=b9bc1646e5364, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Wed Oct 21 14:27:38 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880919, encodeId=6dfd880919f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e37b1737491, createdName=1df00607m15(暂无匿称), createdTime=Sun Aug 30 16:45:49 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025467, encodeId=4b56102546e7b, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Mon Jun 22 18:27:38 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271519, encodeId=621212e1519b5, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494737, encodeId=c99d1494e3756, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592173, encodeId=bc0615921e3b2, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=)]
    2021-04-06 ms5000000426001883

    受教了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=954316, encodeId=aeba9543169b, content=受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/e69ebf6de4ff4c58975eca21defba7f4/998f896c1f9b4f698397a269727651c6.jpg, createdBy=7b2b5391720, createdName=ms5000000426001883, createdTime=Tue Apr 06 21:16:10 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646753, encodeId=b9bc1646e5364, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Wed Oct 21 14:27:38 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880919, encodeId=6dfd880919f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e37b1737491, createdName=1df00607m15(暂无匿称), createdTime=Sun Aug 30 16:45:49 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025467, encodeId=4b56102546e7b, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Mon Jun 22 18:27:38 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271519, encodeId=621212e1519b5, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494737, encodeId=c99d1494e3756, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592173, encodeId=bc0615921e3b2, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=)]
    2020-10-21 changfy
  3. [GetPortalCommentsPageByObjectIdResponse(id=954316, encodeId=aeba9543169b, content=受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/e69ebf6de4ff4c58975eca21defba7f4/998f896c1f9b4f698397a269727651c6.jpg, createdBy=7b2b5391720, createdName=ms5000000426001883, createdTime=Tue Apr 06 21:16:10 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646753, encodeId=b9bc1646e5364, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Wed Oct 21 14:27:38 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880919, encodeId=6dfd880919f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e37b1737491, createdName=1df00607m15(暂无匿称), createdTime=Sun Aug 30 16:45:49 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025467, encodeId=4b56102546e7b, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Mon Jun 22 18:27:38 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271519, encodeId=621212e1519b5, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494737, encodeId=c99d1494e3756, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592173, encodeId=bc0615921e3b2, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=)]
    2020-08-30 1df00607m15(暂无匿称)

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=954316, encodeId=aeba9543169b, content=受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/e69ebf6de4ff4c58975eca21defba7f4/998f896c1f9b4f698397a269727651c6.jpg, createdBy=7b2b5391720, createdName=ms5000000426001883, createdTime=Tue Apr 06 21:16:10 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646753, encodeId=b9bc1646e5364, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Wed Oct 21 14:27:38 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880919, encodeId=6dfd880919f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e37b1737491, createdName=1df00607m15(暂无匿称), createdTime=Sun Aug 30 16:45:49 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025467, encodeId=4b56102546e7b, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Mon Jun 22 18:27:38 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271519, encodeId=621212e1519b5, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494737, encodeId=c99d1494e3756, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592173, encodeId=bc0615921e3b2, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=)]
    2020-06-22 独孤立克

    干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=954316, encodeId=aeba9543169b, content=受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/e69ebf6de4ff4c58975eca21defba7f4/998f896c1f9b4f698397a269727651c6.jpg, createdBy=7b2b5391720, createdName=ms5000000426001883, createdTime=Tue Apr 06 21:16:10 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646753, encodeId=b9bc1646e5364, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Wed Oct 21 14:27:38 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880919, encodeId=6dfd880919f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e37b1737491, createdName=1df00607m15(暂无匿称), createdTime=Sun Aug 30 16:45:49 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025467, encodeId=4b56102546e7b, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Mon Jun 22 18:27:38 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271519, encodeId=621212e1519b5, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494737, encodeId=c99d1494e3756, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592173, encodeId=bc0615921e3b2, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=954316, encodeId=aeba9543169b, content=受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/e69ebf6de4ff4c58975eca21defba7f4/998f896c1f9b4f698397a269727651c6.jpg, createdBy=7b2b5391720, createdName=ms5000000426001883, createdTime=Tue Apr 06 21:16:10 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646753, encodeId=b9bc1646e5364, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Wed Oct 21 14:27:38 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880919, encodeId=6dfd880919f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e37b1737491, createdName=1df00607m15(暂无匿称), createdTime=Sun Aug 30 16:45:49 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025467, encodeId=4b56102546e7b, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Mon Jun 22 18:27:38 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271519, encodeId=621212e1519b5, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494737, encodeId=c99d1494e3756, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592173, encodeId=bc0615921e3b2, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=)]
    2020-06-21 俅侠
  7. [GetPortalCommentsPageByObjectIdResponse(id=954316, encodeId=aeba9543169b, content=受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201016/e69ebf6de4ff4c58975eca21defba7f4/998f896c1f9b4f698397a269727651c6.jpg, createdBy=7b2b5391720, createdName=ms5000000426001883, createdTime=Tue Apr 06 21:16:10 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646753, encodeId=b9bc1646e5364, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Wed Oct 21 14:27:38 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880919, encodeId=6dfd880919f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e37b1737491, createdName=1df00607m15(暂无匿称), createdTime=Sun Aug 30 16:45:49 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025467, encodeId=4b56102546e7b, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Mon Jun 22 18:27:38 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271519, encodeId=621212e1519b5, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494737, encodeId=c99d1494e3756, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592173, encodeId=bc0615921e3b2, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Sun Jun 21 09:27:38 CST 2020, time=2020-06-21, status=1, ipAttribution=)]

相关资讯

PNAS:c-Myc-SIRT1通道是癌细胞无限分裂的分子机制

近日,国际著名杂志PNAS刊登了德国慕尼黑大学等机构的研究人员的最新研究成果“The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop。”,文章中,研究人员揭示了癌细胞无限分裂的一种分子机制。 癌细胞最显著

Nat Commun:中国科大高平和张华凤课题组为临床肿瘤治疗提供了潜在的新靶点

近日,国际学术权威刊物自然出版集团旗下子刊《Nature Communications》杂志上在线发表了中国科学技术大学生命科学学院高平课题组和张华凤课题组题为Menin enhances c-Myc-mediated transcription to promote cancer progression 研究成果,论文报道了在肿瘤代谢基因调控研究领域取得新进展。论文的第一作者为高平课题组的博士生

Heart:c-MyC是主动脉狭窄患者心肌损伤和纤维化的新标志物!

由此可见,血清c-MyC浓度与主动脉狭窄患者的心肌肥厚、纤维化和死亡风险增加相关。血清肌小节蛋白浓度的量化为评估疾病的严重程度提供了客观的指标,并且其在监测主动脉瓣狭窄进展中的临床价值值得进一步研究。

J Clin Invest:发现淋巴瘤细胞逃避程序性死亡新途径

       一个名为“未折叠蛋白响应(Unfolded Protein Response,UPR)”的信号通路是细胞对其内部未折叠或错误折叠的蛋白质产生响应的程序,能够帮助肿瘤细胞在淋巴瘤的发展过程中逃避程序性细胞死亡。         本项研究由美国宾西法尼亚大学佩雷尔曼医学院放射肿瘤学系的助理

J Exp Clin Cancer Res:肝癌转化医学领域新进展

近日,中国科学院大连化学物理研究所生物技术研究部转化医学科学研究中心疾病基因组学研究组(1832组)研究员刘扬团队在肿瘤转化医学领域取得新进展,该团队揭示了EGFR/ERK信号通路调控肝癌细胞产生耐药性的分子机制,并提供了可用于治疗肝癌的新临床策略和方法。相关研究结果发表于J Exp Clin Cancer Res上。